WallStSmart

Ironwood Pharmaceuticals Inc (IRWD)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 4729% more annual revenue ($14.30B vs $296.15M). IRWD leads profitability with a 8.1% profit margin vs -24.6%. VTRS earns a higher WallStSmart Score of 50/100 (C-).

IRWD

Hold

47

out of 100

Grade: D+

Growth: 3.3Profit: 6.0Value: 8.3Quality: 5.0

VTRS

Buy

50

out of 100

Grade: C-

Growth: 3.3Profit: 3.5Value: 6.7Quality: 5.5
Piotroski: 4/9Altman Z: 0.80
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IRWDUndervalued (+36.8%)

Margin of Safety

+36.8%

Fair Value

$7.02

Current Price

$3.04

$3.98 discount

UndervaluedFair: $7.02Overvalued

Intrinsic value data unavailable for VTRS.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IRWD0 strengths · Avg: 0/10

No standout strengths identified

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1410/10

Growing faster than its price suggests

Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Areas to Watch

IRWD3 concerns · Avg: 2.3/10
Market CapQuality
$495.70M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-5.8%2/10

ROE of -5.8% — below average capital efficiency

Revenue GrowthGrowth
-47.3%2/10

Revenue declined 47.3%

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-21.1%2/10

ROE of -21.1% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.802/10

Distress zone — elevated risk

Profit MarginProfitability
-24.6%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : IRWD

IRWD has a balanced fundamental profile.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.

Bear Case : IRWD

The primary concerns for IRWD are Market Cap, Return on Equity, Revenue Growth.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

IRWD profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.

VTRS carries more volatility with a beta of 0.80 — expect wider price swings.

VTRS is growing revenue faster at 5.0% — sustainability is the question.

VTRS generates stronger free cash flow (551M), providing more financial flexibility.

Bottom Line

VTRS scores higher overall (50/100 vs 47/100). IRWD offers better value entry with a 36.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ironwood Pharmaceuticals Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?